Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: A multicenter real-life HER2PATH study

Basit Öğe Kaydı
dc.authorid0000-0002-0443-6966
dc.authorid0000-0001-7934-7039
dc.contributor.authorBilici, Ahmet
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorKaplan, Muhammed Ali
dc.contributor.authorÖksüzoğlu, Berna
dc.contributor.authorSezer, Ahmet
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorÇubukçu, Erdem
dc.contributor.authorŞendur, Mehmet Ali Nahit
dc.contributor.authorAksoy, Sercan
dc.contributor.authorDemirci, Umut
dc.date.accessioned2024-03-13T11:10:00Z
dc.date.available2024-03-13T11:10:00Z
dc.date.issued2023
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractAimTo investigate the pathological complete response (pCR) achieved after neoadjuvant therapy with versus without adding pertuzumab (P) to trastuzumab (H) plus neoadjuvant chemotherapy (NCT) in HER2+ breast cancer (BC) patients in a real-life setting.MethodsA total of 1528 female HER2+ BC patients who received NCT plus H with or without P were included in this retrospective real-life study. Primary endpoint was pCR rate (ypT0/Tis ypN0). Clinicopathological characteristics, event-free survival (EFS) time, and relapse rates were evaluated with respect to HER2 blockade (NCT-H vs. NCT-HP) and pCR.ResultsOverall, 62.2% of patients received NCT-H and 37.8% received NCT-HP. NCT-HP was associated with a significantly higher pCR rate (66.4 vs. 56.8%, p < 0.001) and lower relapse (4.5 vs. 12.2%, p < 0.001) in comparison to NCT-H. Patients with pCR had a significantly lower relapse (5.6 vs. 14.9%, p < 0.001) and longer EFS time (mean(SE) 111.2(1.9) vs. 93.9(2.7) months, p < 0.001) compared to patients with non-pCR. Patients in the NCT-HP group were more likely to receive docetaxel (75.0 vs. 40.6%, p < 0.001), while those with pCR were more likely to receive paclitaxel (50.2 vs. 40.7%, p < 0.001) and NCT-HP (41.5 vs. 32.1%, p < 0.001). Hormone receptor status and breast conservation rates were similar in NCT-HP vs. NCT-H groups and in patients with vs. without pCR. Invasive ductal carcinoma (OR, 2.669, 95% CI 1.596 to 4.464, p < 0.001), lower histological grade of the tumor (OR, 4.052, 95% CI 2.446 to 6.713, p < 0.001 for grade 2 and OR, 3.496, 95% CI 2.020 to 6.053, p < 0.001 for grade 3), lower T stage (OR, 1.959, 95% CI 1.411 to 2.720, p < 0.001) and paclitaxel (vs. docetaxel, OR, 1.571, 95% CI 1.127 to 2.190, p = 0.008) significantly predicted the pCR.ConclusionsThis real-life study indicates that adding P to NCT-H enables higher pCR than NCT-H in HER2+ BC, while pCR was associated with lower relapse and better EFS time.
dc.identifier.citationBilici, A., Ölmez, Ö. F., Kaplan, M. A., Öksüzoğlu, B., Sezer, A., Karadurmuş, N. ... Demirci, U. (2023). Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: A multicenter real-life HER2PATH study. Acta Oncologica, 62(4), 381-390. https://dx.doi.org/10.1080/0284186X.2023.2202330
dc.identifier.doi10.1080/0284186X.2023.2202330
dc.identifier.endpage390
dc.identifier.issn0284-186X
dc.identifier.issn1651-226X
dc.identifier.issue4
dc.identifier.pmid37083566
dc.identifier.startpage381
dc.identifier.urihttps://dx.doi.org/10.1080/0284186X.2023.2202330
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12365
dc.identifier.volume62
dc.identifier.wos000971681800001en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.institutionauthorBilici, Ahmet
dc.institutionauthorÖlmez, Ömer Fatih
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofActa Oncologicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectHER2 Protein Positive
dc.subjectBreast Cancer
dc.subjectNeoadjuvant Treatment
dc.subjectPertuzumab
dc.subjectTrastuzumab
dc.subjectEvent-Freesurvival
dc.subjectRelapse
dc.subjectReal-Wordevidence
dc.titleImpact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: A multicenter real-life HER2PATH study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Bilici-Ahmett-2023.pdf
Boyut:
2.07 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu